CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 71 enrolled
Drug / intervention
Buprenorphine and Outpatient Parenteral Antibiotic Therapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04677114
NCT04677114Phase 2Completed

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

Laura Fanucchi·interventional·Posted Dec 21, 2020·Updated Apr 28, 2026

In Brief

A Phase 2 clinical trial evaluating Buprenorphine and Outpatient Parenteral Antibiotic Therapy and Buprenorphine and standard of care antibiotic treatment for Drug Use and Opioid-use Disorder. Completed, enrolled 71 participants across 1 site.

Detailed Summary

This study will assess the efficacy of an integrated outpatient treatment model for persons with opioid use disorder and injection related infections. The investigators hypothesize that outpatient antibiotic treatment coupled with comprehensive treatment for opioid use disorder will demonstrate a safe and effective way to manage patients. Results could improve the current protocols for the treatment of individuals with opioid use disorder and severe infections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedDec 21, 2020
Enrollment StartMar 16, 2021
Primary CompletionMar 6, 2025
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 5.5 years ago

Interventions

Buprenorphine and Outpatient Parenteral Antibiotic Therapydrug

Participants will be complete IV antibiotics with OPAT. All participants will receive buprenorphine treatment of OUD.

Buprenorphine and standard of care antibiotic treatmentdrug

All participants will receive treatment of OUD and the infection per usual clinical care.